Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Noda, Kazumasa; Nishiwaki, Yutaka; Kawahara, Masaaki; Negoro, Shunichi; Sugiura, Takahiko; Yokoyama, Akira; Fukuoka, Masahiro; Mori, Kiyoshi; Watanabe, Koshiro; Tamura, Tomohide; Yamamoto, Seiichiro; Saijo, Nagahiro

doi:10.1056/nejmoa003034

Public

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

Published in New England Journal of Medicine • Jan 10, 2002

Authors:

Kazumasa Noda

Yutaka Nishiwaki

Masaaki Kawahara

Abstract

BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. In a phase 2 study of irinotecan plus cisplatin in patients with extensive small-cell lung cancer, there was a high response rate and a promising median survival time. METHODS: We conducte...

Subject

Irinotecan

Cisplatin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!